Acumen Pharmaceuticals ABOS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.01 (+0.81%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Acumen Pharmaceuticals (ABOS)
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.25

  • Market Cap

    $75.10 Million

  • Price-Earnings Ratio

    -2.50

  • Total Outstanding Shares

    60.08 Million Shares

  • Total Employees

    52

  • Dividend

    No dividend

  • IPO Date

    July 1, 2021

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    427 park st., Charlottesville, VA, 22902

  • Homepage

    https://www.acumenpharm.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-24.60 Million
Net Cash Flow From Investing Activities$-10.13 Million
Net Cash Flow From Financing Activities$-42,000
Net Cash Flow From Financing Activities, Continuing$-42,000
Net Cash Flow From Investing Activities, Continuing$-10.13 Million
Net Cash Flow, Continuing$-34.77 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Nonoperating Income/Loss$2.50 Million
Research and Development$27.25 Million
Diluted Earnings Per Share$-0.50
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Net Income/Loss$-29.77 Million
Net Income/Loss Available To Common Stockholders, Basic$-29.77 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$-29.08 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss Attributable To Parent$-29.08 Million
Comprehensive Income/Loss$-29.08 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Accounts Payable$2.34 Million
Assets$266.98 Million
Wages$2.78 Million
Equity Attributable To Parent$217.20 Million
Noncurrent Assets$59.34 Million
Equity Attributable To Noncontrolling Interest$0

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ABOS from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.